Skip to main content

Table 1 Antibody response (*) by neutralizing anti-SARS-CoV-2 IgG titrations and response rates (with ≥ 15 AU/mL constituting a positive result) in myelofibrosis versus essential thrombocythemia (ET)/polycythemia vera (PV)

From: Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

 

Myelofibrosis (n = 10)

ET and PV (n = 32)

p

Day 0 (first dose)

 Geometric mean concentration (95% CI), AU/mL

4.20 (3.8–4.93)

4.18 (3.87–4.65)

0.716**

Day 21 (second dose)

 Geometric mean concentration (95% CI), AU/mL

5.76 (4.22–8.78)

21.83 (16.22–29.72)

0.001**

 Seroconversion rate (i.e., Responders), n (%)

1 (10)

22 (68.8)

0.002***

Day 35 (two weeks after second dose)

 Geometric mean concentration (95% CI), AU/mL

32.47 (12.09–84.58)

217.97 (135.07–324.35)

0.003**

 Seroconversion rate (i.e., Responders), n (%)

6 (60%)

30 (93.8%)

0.021***

  1. Bold values are statistically significant
  2. *Serology testing was performed with the Liaison® SARS-CoV-2 S1/S2 IgG assay (DiaSorin®, Saluggia, Italy); **p value has been calculated by using Mann–Whitney nonparametric test; ***p value has been calculated using Fisher’s exact test